Reviewing meds with a pharmacist may boost adherence

Engaging Medicare members associated with improved adherence: Part of the Star rating composite score

How well do medication management therapy (MTM) programs work? This study showed that members who completed comprehensive medication reviews (CMRs), as part of a MTM program, improved the percentage of adherent members. 40% more members were adherent. (Adherence was defined as having a proportion of days covered over 80%.) Adherence was measured for medications to treat diabetes, high blood pressure and high cholesterol.

Medication Therapy Management (MTM) Comprehensive Medication Review (CMR) Impact Assessment (Fall 2015)

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

April 25, 2024

Drug Approvals Monthly Update: April 2024

This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals…

Perspectives

April 24, 2024

Prime/MRx resident wins AMCP Foundation Best Poster Award

Ai Quynh Nguyen, PharmD, was recently recognized for her research on opioid-prescribing patterns and outcomes

Perspectives

April 23, 2024

Expert Clinical Network Insights: April 2024

A look into our Expert Clinical Network (ECN) – part of Prime/MRx’s value-based approach to medical and pharmacy benefit management that offers access to more than 175 national and world-renowned key opinion leaders in multiple disease categories who provide expertise on challenging prior authorization case reviews, peer-to-peer discussions, drug policy development and formulary guidance

View all news